Featured Stories
Bristol’s Integration Strategy With Celgene Includes “Ring-Fencing” Oncology Teams
Firm hopes to minimize merger disruption by maintaining separate BMS, Celgene cancer expertise. Opdivo posts solid growth, but longer-term worries persist.
AbbVie CEO Upbeat On Skyrizi Commercialization, Raises Financial Guidance
AbbVie’s product pipeline may be delivering just in time to alleviate concerns about loss of exclusivity on its best-selling product, Humira.
Divest, Refocus, Transition: Multinationals Embark On Uncharted Path In China
Facing unprecedented pricing pressures in China, multinationals are embarking on a major shift away from mature products to focus more on innovative drugs, but there are major challenges linked to the transition that won’t be easy to navigate, notes a new report.
Latest News
Recent Tweets from ScripEmbedding Time-Critical Scheduling in Drug Production
Manufacturing is the engine room of the pharmaceutical industry. Ultimately, a medicine has little value if it does not reach patients on schedule, in the required quantity and quality. Download this whitepaper which discusses time-critical scheduling in drug production.
Commercial Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
China Pharma Sales Bring Bayer Relief From Monsanto Legal Woes
Xarelto and Eylea are continuing to sell well but the German major faces another heap of litigation in the US over Monsanto's weedkillers which is alarming shareholders.
Taltz Results In Spondyloarthritis Add To Lilly Franchise Hopes
Taltz has sailed through the latest trial in Lilly’s COAST program, in non-radiographic axial spondyloarthritis, but choppy waters may be ahead; meanwhile, Lilly signs an immunology deal with Avidity Biosciences.
AbbVie’s Humira Succession Plan Begins Taking Shape With Skyrizi US Approval
Central to AbbVie’s plans to endure biosimilar erosion to Humira, Skyrizi gets US approval in psoriasis, with approval of upadacitinib expected in RA this year.
Biogen Stays Steady As Alzheimer’s Programs Falter
Piramal’s Sensipar Generic Blocked In US, For Now
Piramal halted sales of its generic version of Amgen’s Sensipar following a US court order that also required Amgen to furnish a $39m bond. The Sensipar generic launch landscape continues to be complex with multiple legal challenges, including those from Cipla and Sun at various stages.
Novartis CEO Issues Staunch Defense of Zolgensma As Sales Soar
The Swiss major has got off to a strong start in 2019 with Cosentyx and Entresto sales soaring and Mayzent – and possibly very soon Zolgensma – getting US approvals.
Hepalink-Backed HighTide Bets On NASH For Global Markets
Emerging Company Profile: Fatty liver disease has been a hot development area that keeps getting more attention, and one Chinese startup backed by the world’s largest heparin manufacturer is looking to launch a new therapy globally.
Bristol’s Focus Returns To IO Following Celgene Vote
Q1 Earnings Preview: With the positive vote on its merger with Celgene behind it, Bristol now needs to focus on growing its immuno-oncology business, where several upcoming catalysts could bolster Opdivo.
Policy & Regulation Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Lilly’s Lartruvo Withdrawal Stirs Questions About Payment For Accelerated Approval Drugs
News that the soft tissue sarcoma drug will come off the market after its confirmatory trial failed to verify clinical benefit spurs Memorial Sloan-Kettering’s Peter Bach to ask whether Lilly will refund money to payers.
India New Trial Rules - Sponsors Interested But 'FAQ' Could Help
India’s new clinical trial regulations could revive sponsor interest in the country, but some norms around local Phase III trial waivers appear open to interpretation and could potentially weigh down momentum.
Gelesis's Obesity Product FDA Acceptance Gives Boost To PureTech's Portfolio
PureTech's affiliate Gelesis has received FDA clearance for its Plenity capsule to treat overweight-obese adults, and plans to launch it commercially in the second half.
Insulin Assistance Programs: Big Help Or Just A Band-Aid?
Drug makers and other stakeholders have been rolling out insulin savings programs as the high cost of insulins come under scrutiny on Capitol Hill. Sanofi announced an expanded cost-savings program during a House hearing, but one Congresswoman called them a band-aid.
Research & Development Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Another NASH Failure: Gilead’s Hits Keep Coming
BIO-Europe Spring 2019: Sterna CEO On Raising Cash For Pipeline Progress
During BIO-Europe Spring 2019, Christian Pangratz, CEO of sterna biologicals, talks to Lucie Ellis, executive editor of In Vivo, about the company's pipeline of immunology-focused assets.
Teva’s Ajovy Failure In Cluster Headaches Good For Lilly’s CGRP Inhibitor Emgality
Lilly's Emgality looks set to benefit from Teva ending clinical development of its CGRP antibody competitor in cluster headaches due to lack of efficacy in Phase III.
The 2019 Worldwide Pharma & Biotech Industry R&D Scene
INFOGRAPHIC: A snapshot of the industry in key performance indicators, taken in early 2019.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.